



(51) International Patent Classification:

<i>A61K 35/17</i> (2015.01)	<i>C12N 15/12</i> (2006.01)
<i>A61K 48/00</i> (2006.01)	<i>C07K 14/82</i> (2006.01)

(21) International Application Number:

PCT/US2021/060873

(22) International Filing Date:

24 November 2021 (24.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/118,554	25 November 2020 (25.11.2020)	US
63/147,718	09 February 2021 (09.02.2021)	US

(71) Applicant: **GENEUS BIOTECHNOLOGY, INC.**
[US/US]; 12 Michigan Drive, Natick, Massachusetts 01760
(US).

(72) **Inventors:** **SLANETZ, Alfred E.**; 12 Michigan Drive, Natick, Massachusetts 01760 (US). **BARRY, Walter**; 12 Michigan Drive, Natick, Massachusetts 01760 (US).

(74) **Agent: MORRIS, Patrick D.**; Perkins Coie LLP, P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME




FIG. 1

(57) Abstract: In various embodiments, the present disclosure provides T cell compositions comprising T cells that encode and/or express a T cell receptor (TCR) that binds to a neoantigen associated with a subject's cancer, and are useful for adoptive immunotherapy. Also disclosed are methods for making and/or using T cell compositions described herein.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

14 July 2022 (14.07.2022)